IFNG and acute myeloid leukemia: Furthermore, the hypomethylating agent, azacitidine, enhances immune responses by increasing interferon gamma (IFN-γ) production and major histocompatibility complex (MHC) expression, and is now being used in combination with PD1 blockade in AML treatment with modest improvement in survival [11, 12].